Related Experiment Videos
Mismatch repair and drug responses in cancer
W. David Sedwick1, Sanford D. Markowitz, Martina L. Veigl
1Department of Medicine, Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH
Abstract:
Defects in mismatch repair contribute to development of approximately 15% of colon cancers and to origination of endometrial, gastric and other cancers. Tumors with defects in mismatch repair exhibit marked resistance to alkylators and a variety of anticancer agents that modify DNA to create substrates for the mismatch repair system. These altered drug responses appear to derive from requirements for mismatch repair proteins in signalling apoptosis, altered cell cycle checkpoint behaviour and/or loss of mismatch repair dependent toxicity arising from futile repair cycling. Altered repair mechanisms for mismatched substrates in mismatch repair defective tumors provide both challenges for development of tumor-phenotype-screening methodologies to assure appropriate therapy is administered for these cancers and foci for development of new therapy approaches that capitalize on modified drug responses in mismatch repair- defective cells. Copyright 1999 Harcourt Publishers Ltd.
Insights
Defects in DNA mismatch repair (MMR) are linked to 15% of colon cancers and other tumors. MMR-deficient tumors show resistance to certain DNA-damaging anticancer drugs, impacting treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Defects in DNA mismatch repair (MMR) are implicated in approximately 15% of colon cancers, as well as endometrial and gastric cancers.
- Tumors with MMR defects display significant resistance to alkylating agents and other anticancer drugs that target DNA.
- This resistance is associated with the role of MMR proteins in apoptosis signaling, cell cycle checkpoint control, and the toxicity of futile repair cycles.
Purpose of the Study:
- To explore the implications of mismatch repair defects in cancer development and drug response.
- To investigate the mechanisms underlying drug resistance in MMR-deficient tumors.
- To identify challenges and opportunities for developing new therapeutic strategies targeting MMR-defective cancers.
Main Methods:
- Analysis of tumor characteristics associated with mismatch repair deficiency.
- Evaluation of drug response patterns in MMR-defective versus MMR-proficient cancer models.
- Investigation of cellular signaling pathways, including apoptosis and cell cycle checkpoints, in relation to MMR status.
Main Results:
- MMR defects are a key factor in a subset of major human cancers.
- A distinct pattern of drug resistance to DNA-modifying agents is observed in MMR-deficient tumors.
- Mechanisms involve altered apoptosis signaling, cell cycle control, and repair pathway activity.
Conclusions:
- Mismatch repair status is a critical determinant of cancer treatment efficacy.
- Understanding MMR deficiency offers avenues for developing novel cancer therapies.
- Targeting MMR-defective pathways could overcome drug resistance and improve patient outcomes.